Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment

Advances in Experimental Medicine and Biology

Volumn 527, Issue , 2003, Pages 287-295

  Forrest, Caroline M ^a   Kennedy, Alan ^a   Stone, Trevor W ^a   Stoy, Nicholas ^b   Darlington, L Gail ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b EPSOM GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; CALCIUM; ETIDRONIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; METHOTREXATE; NEOPTERIN; PREDNISOLONE; RALOXIFENE; TRYPTOPHAN; XANTHURENIC ACID;

AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; ERYTHROCYTE SEDIMENTATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID PEROXIDATION; OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 1042291129     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0135-0_32     Document Type: Conference Paper

References (40)

1. M. Feldmann, F.M. Brennan, R.N. Maini, Role of cytokine in rheumatoid arthritis, Ann. Rev. Immunol. 14, 397-440 (1996).
2. M.W. Taylor, G. Feng, Relationship between interferon-γ, indoleamine-2,3-dioxygenase and tryptophan catabolism, FASEB J. 5, 2516-2522 (1991).
3. T.W. Stone, The neuropharmacology of quinolinic acid and kynurenic acids, Pharmacol. Revs. 45, 309-379 (1993).
4. T.W. Stone, Kynurenines in the CNS - from obscurity to therapeutic relevance, Progr. Neurobiol. 64, 185-218 (2001).
5. T.W. Stone, M.N. Perkins, Quinolinic acid: a potent endogenous excitant at amino acid receptors in the CNS, Europ. J. Pharmacol. 72, 411-412 (1981).
6. M.N. Perkins, T.W. Stone, An iontophoretic investigation of the action of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247, 184-187 (1983).
7. S.S. Gill, R.W. Mueller, R.F. McGuire, O.M. Pulido, Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity, Toxicol. Pathol. 28, 277-284 (2000).
8. D.J. Mason, L.J. Suva, P.G. Genever, A.J. Patton, S. Steuckle, R.A. Hillam, T.M. Skerry T.M., Mechanically regulated expression of a neural glutamate transporter in bone: a role for excitatory amino acids as osteotropic agents? Bone 20, 199-205 (1997).
9. A.J. Patton, P.G. Genever, M.A. Birch, L.J. Suva, T.M. Skerry, Expression of an NMDA type receptor by human and rat osteoblasts suggests a novel glutamate signalling pathway in bone, Bone 22, 645-649 (1998).
10. C.L. Eastman, T.R. Guilarte, The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine, Neurochem. Res. 15, 1101-1107 (1990).
11. I. S. Okuda, N. Nishiyama, H. Saito, H. Katsuki, Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine, Proc. Nat. Acad. Sci (USA) 93, 12553-12558 (1996).
12. S.R. Thomas, R. Stocker R., Redox reactions related to indoleamine-2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway, Redox Report 4, 199-220 (1999).
13. F.C. Arnett, S.M. Edworth, D.A. Block, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, N.H. Liang, H.S. Lethra, T.A. Medsgar, D.M. Mitchell, D.H. Neustadt, R.S. Pinals, J.G. Schaller, J.T. Sharp, R.L. Wilder, G.G. Hunder, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum. 31, 315-324 (1988).
14. WHO, Assessment of fracture risk and its application to screening for post-menopausal osteoporosis: technical report series 843, WHO, Geneva (1994).
15. M.P. Heyes, K. Saito, O. Devinsky, N.S. Nadi, Kynurenine pathway metabolites in CSF and serum in complex partial seizures, Epilepsia 35, 251-257 (1994).
16. M. Huengsberg, J.B. Winer, M. Gompels, R. Round, J. Ross, M. Shahmanesh, Serum-to-kynurenine ratio increases with progressive disease in HIV-infected patients, Clin. Chem. 44, 858-862 (1998).
17. B. Widner, F. Leblhuber, J. Walli, G.P. Tilz, U. Demel, D. Fuchs, Tryptophan degradation and immune activation in Alzheimer's disease, J. Neural Transm. 107, 343-353 (2000).
18. B. Widner, N. Sepp, E. Kowald, U. Ortner, B. Wirleitner, P. Fritsch, G. Baier-Bitterlich, D. Fuchs, Enhanced tryptophan degradation in systemic lupus erythematosus, Immunobiology 201, 621-630 (2000).
19. H. Kazda, N. Taylor, D. Healy, D. Walker, Maternal, umbilical and amniotic fluid concentrations of tryptophan and kynurenine after labor or cesarean section, Pediat. Res. 44, 368-373 (1998).
20. K. Saito, S. Fujigaki, M.P. Heyes, K. Shibata, M. Takemura, H. Fujii, H. Wada, A. Noma, M. Seishima, Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency, Amer. J. Physiol. 279, F565-F572 (2000).
21. R.J. Truscott, A.J. Elderfield, Relationship between serum tryptophan and tryptophan metabolite levels after tryptophan ingestion in normal subjects and age-related cataract patients, Clin. Sci. 89, 591-599 (1995).
22. C. Herve, P. Beyne, H. Jamault, E. Delacoux, Determination of tryptophan and its kynurenine pathway metabolites in human serum by HPLC with simultaneous UV and fluorimetric detection, J. Chromatog. 675, 157-161 (1996).
23. J.H. Flinn, J.M. Price, N. Yess, R.R. Brown, Excretion of tryptophan metabolites by patients with rheumatoid arthritis, Arthritis Rheum. 7, 201-210 (1964).
24. I.M. Bett, Urinary tryptophan metabolites in rheumatoid arthritis and some other diseases. Ann. Rheum. Dis. 25, 556-562 (1966).
25. R.S. Pinals, Tryptophan metabolism in rheumatic disease, Arthritis Rheum. 7, 662-669 (1964).
26. H. Spiera, R. Vallarino, Serum kynurenine in rheumatoid arthritis, J. Clin. Invest. 48, 856-859 (1969)
27. D. Labdarios, D. Y. McKenzie, J.W.T. Dickerson, D.V. Parke, Metabolic abnormalities of tryptophan and nicotinic acid in patients with rheumatoid arthritis, Rheumatol. Rehab. 17, 227-232 (1978).
28. T. Igari, M. Tsuchizawa, T. Shimamura, Alteration of tryptophan metabolism in the synovial fluid of patients with rheumatoid arthritis and osteoarthritis, Tohoku J. Exp. Med. 153, 79-86 (1987).
29. D.G. Malone, P.W. Dolan, R.R. Brown, M.V. Kalayoglu, R.A. Arend, G.I. Byrne, Y. Ozaki, Interferon-γ induced production of IDO in cultured human synovial cells, J. Rheumatol. 21, 1011-1019 (1994).
30. A. Bertazzo, L. Punzi, N. Bertazzolo, M. Pianon, A. Pozzuoli, C.V.L. Costa, G. Allegri, Tryptophan catabolism in synovial fluids of various arthopathies and its relationship with inflammatory cytokines, Adv. Exp. Med. Biol. 467, 565-570 (1999).
31. Z.Z. Altindag, G. Sahin, F. Inanici, Z. Hascelik, Urinary neopterin excretion and dihydropteridine reductase activity in rheumatoid arthritis, Rheumatol. Intern. 18, 107-111 (1998).
32. H.L. Nurcombe, R.C. Bucknall, S.W. Edwards, Neutrophils isolated from the synovial fluid of patients with rheumatoid arthritis: priming and activation in vivo, Ann.Rheum.Dis. 50, 147-153 (1991).
33. M.L. Tiku, J.B. Liesch, F.M. Robertson, Production of hydrogen peroxide by rabbit articular chondrocytes. Enhancement by cytokines, J. Immunol. 145, 690-696 (1990).
34. D.R. Blake, N.D. Hall, D.A. Treby, B. Halliwell, J.M.C. Gutteridge, Protection against superoxide and hydrogen peroxide in synovial fluid from rheumatoid patients, Clin. Sci. 61, 483-486 (1981).
35. R. Miesel, M. Zuber, Elevated levels of xanthine oxidase in serum of patients with inflammatory and autoimmune rheumatic diseases, Inflammation 17, 551-561 (1993).
36. H. Kaur, S.E. Edmonds, D.R. Blake, B. Halliwell, Hydroxyl radical generation by rheumatoid blood and knee joint synovial fluid, Ann. Rheum. Dis. 55, (supp): 915-920 (1996).
37. D.A. Rowley, J.M.C. Gutteridge, D.R. Blake, M. Farr, B. Halliwell, Lipid peroxidation in rheumatoid arthritis: thiobarbituric acid - reactive material and catatylic iron salts in synovial fluid from rheumatoid patients, Clin. Sci. 66, 691-695 (1984).
38. M. Uesugi, T. Hayashi, H.E. Jasin, Covalent cross-linking of immune complexes by oxygen radicals and nitrite, J. Immunol. 161, 1422-1427 (1998).
39. M. Zuber, R. Miesel, Xanthine oxidase and sulfhydryls and the antirheumatic action of xanthine oxidase inhibitor allopurinol in the animal model of collagen (II) arthritis, Aktuelle Rheumatol. 19, :90-98 (1994).
40. R. Miesel, R. Hartung, H. Kroeger, Priming of NADPH oxidase by tumor necrosis factor alpha in patients with inflammatory and autoimmune rheumatic diseases, Inflammation 20, 427-438 (1996).